The article you link has this information:
"The final analysis found that after a median follow-up period of 20.2 months, the median OS in patients in the abiraterone arm of the study was 15.8 months (95% CI, 14.8–17.0) compared with 11.2 months in the placebo arm".
These are different numbers than the graph.
OK, I found the difference. There was an interim analysis as the trial was continuing. This decision to analyze is made by an independent group controlling the trial. At that point they found the data which is in your graph and which Zytiga copies at their commercial site. This was the basis of the submission to the FDA, as it appeared statistically significant that Abiraterone made a difference n survival. As the FDA considered this the trial data continued to accumulate. After approval a further, final analysis was conducted. This set of numbers is that which the news article refers in your link at the top.
Even more confusingly, Zytiga themselves use the interim data for the Kaplan-Meier graphat their site, while just above the graph printing the LARGE, bold, green numbers and survival from the final analysis, ensuring that anyone trying to reconcile the large numbers with the graph below will be unsuccessful. Whew.
I think a take-away here is that information from the drug makers may be incomplete, confusing, or both.
Post Edited (tarhoosier) : 2/27/2013 11:41:55 AM (GMT-7)